MX381542B - Métodos y composiciones para el tratamiento de la infección por el virus del zika. - Google Patents

Métodos y composiciones para el tratamiento de la infección por el virus del zika.

Info

Publication number
MX381542B
MX381542B MX2018010707A MX2018010707A MX381542B MX 381542 B MX381542 B MX 381542B MX 2018010707 A MX2018010707 A MX 2018010707A MX 2018010707 A MX2018010707 A MX 2018010707A MX 381542 B MX381542 B MX 381542B
Authority
MX
Mexico
Prior art keywords
methods
compositions
zika virus
virus infection
treatment
Prior art date
Application number
MX2018010707A
Other languages
English (en)
Spanish (es)
Other versions
MX2018010707A (es
Inventor
Pravin L Kotian
Shanta Bantia
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2018010707A publication Critical patent/MX2018010707A/es
Publication of MX381542B publication Critical patent/MX381542B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2018010707A 2016-03-06 2017-03-06 Métodos y composiciones para el tratamiento de la infección por el virus del zika. MX381542B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662304317P 2016-03-06 2016-03-06
US201662324180P 2016-04-18 2016-04-18
US201662368111P 2016-07-28 2016-07-28
US201662370697P 2016-08-03 2016-08-03
US201662411867P 2016-10-24 2016-10-24
US201662414466P 2016-10-28 2016-10-28
US201762462852P 2017-02-23 2017-02-23
PCT/US2017/020961 WO2017155886A1 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection

Publications (2)

Publication Number Publication Date
MX2018010707A MX2018010707A (es) 2019-03-28
MX381542B true MX381542B (es) 2025-03-04

Family

ID=59789791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010707A MX381542B (es) 2016-03-06 2017-03-06 Métodos y composiciones para el tratamiento de la infección por el virus del zika.

Country Status (9)

Country Link
US (3) US10512649B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426659A4 (cg-RX-API-DMAC7.html)
JP (1) JP7046015B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017229105B2 (cg-RX-API-DMAC7.html)
CA (1) CA3016588A1 (cg-RX-API-DMAC7.html)
MA (1) MA43812A (cg-RX-API-DMAC7.html)
MX (1) MX381542B (cg-RX-API-DMAC7.html)
TW (1) TWI767903B (cg-RX-API-DMAC7.html)
WO (1) WO2017155886A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7416445B2 (ja) * 2019-02-18 2024-01-17 株式会社栄養・病理学研究所 ブタにおけるt細胞の活性化度を評価する方法、ブタにおけるt細胞活性化を評価する剤、ブタt細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
US20100129317A1 (en) 2006-09-11 2010-05-27 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
LT2898885T (lt) * 2010-10-15 2018-02-26 Biocryst Pharmaceuticals, Inc. Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui

Also Published As

Publication number Publication date
TW201731515A (zh) 2017-09-16
US20200085830A1 (en) 2020-03-19
EP3426659A1 (en) 2019-01-16
CA3016588A1 (en) 2017-09-14
US20190083496A1 (en) 2019-03-21
AU2017229105A1 (en) 2018-10-11
JP2019507195A (ja) 2019-03-14
US10512649B2 (en) 2019-12-24
MA43812A (fr) 2018-11-28
JP7046015B2 (ja) 2022-04-01
MX2018010707A (es) 2019-03-28
EP3426659A4 (en) 2019-12-25
TWI767903B (zh) 2022-06-21
WO2017155886A1 (en) 2017-09-14
US11975003B2 (en) 2024-05-07
AU2017229105B2 (en) 2021-08-12
US10933066B2 (en) 2021-03-02
US20210186976A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
EA201890425A1 (ru) Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
EA201990043A1 (ru) Антибактериальные соединения
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
JOP20200004A1 (ar) تركيبات طويلة المفعول
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017004318A (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico.
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
MX388592B (es) Compuestos y metodos terapeuticos.